# A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations

> **NCT07414290** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Vitalgen BioPharma Co., Ltd.** · enrollment: 17 (estimated)

## Conditions studied

- Parkinson Disease (PD)

## Interventions

- **DRUG:** VGN-R08b 4.2×10^13 vg
- **DRUG:** VGN-R08b 8.4×10^13 vg
- **DRUG:** VGN-R08b 1.68×10^14 vg

## Key facts

- **NCT ID:** NCT07414290
- **Lead sponsor:** Shanghai Vitalgen BioPharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-25
- **Primary completion:** 2027-09-01
- **Final completion:** 2031-09-01
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07414290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07414290, "A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07414290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*